Restart Life Sciences (XCNQ:HEAL.X) Total Current Assets : C$0.26 Mil (As of Sep. 2024)

View and export this data going back to 2006. Start your Free Trial

What is Restart Life Sciences Total Current Assets?

Total current assets includes Cash, Cash Equivalents, Marketable Securities, Total Receivables, Total Inventories, and Other Current Assets. Restart Life Sciences's total current assets for the quarter that ended in Sep. 2024 was C$0.26 Mil.

Restart Life Sciences Total Current Assets Historical Data

The historical data trend for Restart Life Sciences's Total Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Restart Life Sciences Total Current Assets Chart

Restart Life Sciences Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Total Current Assets

Get a 7-Day Free Trial

2.16

0.88

2.58

0.33

0.28

Restart Life Sciences Quarterly Data
	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Mar24	Jun24	Sep24
Total Current Assets	Get a 7-Day Free Trial															-	0.04	0.03	0.02	0.26

Restart Life Sciences Total Current Assets Calculation

Total Current Assets are the asset that can be converted to cash or used to pay current liabilities within 12 months.

Restart Life Sciences's Total Current Assets for the fiscal year that ended in Dec. 2022 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	0.267	+	0.008	+	0	+	0.007
	=	0.28

Restart Life Sciences's Total Current Assets for the quarter that ended in Sep. 2024 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	0.251	+	0.006	+	0	+	-0.001
	=	0.26

Total Current Assets is linked to the Current Ratio, which is the result of dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations.

Total Current Assets is also linked to Working Capital, Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Restart Life Sciences (XCNQ:HEAL.X) Total Current Assets Explanation

In Ben Graham's calculation of liquidation value, inventory is only considered worth half of its book value, and accounts receivable is considered worth 75% of its value. Therefore the liquidation value is lower than calculated from total current assets.

Restart Life Sciences's Liquidation Value for the quarter that ended in Sep. 2024 is

	Liquidation value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	0.251	-	0.852	+	0.75 * 0.006	+	0.5 * 0
=	-0.60

Restart Life Sciences Total Current Assets Related Terms

Thank you for viewing the detailed overview of Restart Life Sciences's Total Current Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Restart Life Sciences Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Restart Life Sciences Corp (XCNQ:HEAL.X) » Definitions » Total Current Assets

Comparable Companies

Traded in Other Exchanges

NMLSD:USA HN3:Germany HN3:Germany

Address

700-838 West Hastings Street, Vancouver, BC, CAN, V6C 0A6

Website

https://www.novamentis.ca

Restart Life Sciences Corp is a Canadian life sciences company dedicated to addressing today's health challenges with wellness solutions. It is focus is on creating health foods that address the needs of this community. Its Flagship developments includes Autism Spectrum, Health-Related Foods, Psilocybin Clinical Trial for Fragile X Syndrome, Orphan Drug Designation (FDA and EMA).

Executives

Derek Lloyd Harry Ivany	10% Security Holder, Director, Senior Officer
Steven Feldman	Director
William Rascan	Director, Senior Officer

Restart Life Sciences Headlines

No Headlines